SCHEMBL2851874

SCHEMBL2851874

CCN1CCN(Cc2ccc(NC(=O)Nc3ccc(Oc4ncnc5[nH]cnc45)cc3)cc2C(F)(F)F)CC1

nearest known ligand 0.67

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SRC P12931 6/20 0.67
ABL1 P00519 6/20 0.67
MAP3K7 O43318 5/20 0.67
MAP4K2 Q12851 5/20 0.67
RET P07949 4/20 0.67
KDR P35968 4/20 0.67
MAPK14 Q16539 4/20 0.67
MKNK2 Q9HBH9 4/20 0.67
MKNK1 Q9BUB5 3/20 0.67
CDK2 P24941 2/20 0.67
CDK8 P49336 2/20 0.67
BCR P11274 2/20 0.67
FES P07332 2/20 0.67
FER P16591 2/20 0.67
MAP3K20 Q9NYL2 2/20 0.67
FGFR4 P22455 2/20 0.67
FGFR1 P11362 2/20 0.67
STK25 O00506 1/20 0.67
CIT O14578 1/20 0.67
MAP2K7 O14733 1/20 0.67

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2845348 0.91 MAP3K7 (0.63) SRCABL1MAP3K7MAP4K2RET
SCHEMBL12999411 0.89 ABL1 (0.52) SRCABL1MAP3K7MAP4K2RET
SCHEMBL2848857 0.88 MAPK14 (0.73) SRCABL1MAP3K7MAP4K2RET
SCHEMBL23353589 0.85 MAP3K7 (0.52) SRCABL1MAP3K7MAP4K2RET
SCHEMBL30692254 0.84 MAP3K7 (0.79) SRCABL1MAP3K7MAP4K2MAPK14
SCHEMBL14689771 0.84 MAP3K7 (0.79) SRCABL1MAP3K7MAP4K2MAPK14
SCHEMBL3880675 0.82 MAPK14 (0.71) SRCABL1MAP3K7MAP4K2RET
SCHEMBL4762420 0.82 SRC (0.81) SRCABL1MAP3K7MAP4K2RET
SCHEMBL3183607 0.81 SRC (0.82) SRCABL1MAP3K7MAP4K2RET
SCHEMBL20569489 0.81 ABL1 (0.65) SRCABL1MAP3K7MAP4K2RET

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8592433-B2 Compounds and compositions as protein kinase inhibitors NOVARTIS INTERNATIONAL PHARMACEUTICAL LTD. (BM) 2013-11-26 US claimed
US-20100324062-A1 COMPOUNDS AND COMPOSITIONS AS PROTEIN KINASE INHIBITORS IRM LLC (BM) 2010-12-23 US claimed
US-20100130476-A1 COMPOUNDS THAT INDUCE PANCREATIC BETA-CELL EXPANSION THE SCRIPPS RESEARCH INSTITUTE (US) 2010-05-27 US claimed
US-8592433-B2 Compounds and compositions as protein kinase inhibitors NOVARTIS INTERNATIONAL PHARMACEUTICAL LTD. (BM) 2013-11-26 US disclosed
US-20100324062-A1 COMPOUNDS AND COMPOSITIONS AS PROTEIN KINASE INHIBITORS IRM LLC (BM) 2010-12-23 US disclosed
US-20100324062-A1 COMPOUNDS AND COMPOSITIONS AS PROTEIN KINASE INHIBITORS IRM LLC (BM) 2010-12-23 US disclosed
US-20100130476-A1 COMPOUNDS THAT INDUCE PANCREATIC BETA-CELL EXPANSION THE SCRIPPS RESEARCH INSTITUTE (US) 2010-05-27 US disclosed
WO-2010056907-A2 COMPOUNDS THAT INDUCE PANCREATIC BETA-CELL EXPANSION THE SCRIPPS RESEARCH INSTITUTE (US) 2010-05-20 WO disclosed
EP-1940844-B1 COMPOUNDS AND COMPOSITIONS AS PROTEIN KINASE INHIBITORS IRM LLC (BM) 2009-09-30 EP disclosed
EP-1940844-A2 COMPOUNDS AND COMPOSITIONS AS PROTEIN KINASE INHIBITORS IRM, LLC (BM) 2008-07-09 EP disclosed
WO-2007053343-A2 COMPOUNDS AND COMPOSITIONS AS PROTEIN KINASE INHIBITORS IRM LLC (BM) 2007-05-10 WO disclosed
WO-2007053343-A2 COMPOUNDS AND COMPOSITIONS AS PROTEIN KINASE INHIBITORS IRM LLC (BM) 2007-05-10 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100324062-A1 COMPOUNDS AND COMPOSITIONS AS PROTEIN KINASE INHIBITORS SYK, SRC, FYN SRC 2/4885ABL1 88/4885MAP3K7 50/4885
US-20100130476-A1 COMPOUNDS THAT INDUCE PANCREATIC BETA-CELL EXPANSION IAPP, PNLIP, GPR119 SRC 4102/4885ABL1 4780/4885MAP3K7 1968/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.